Biomea Fusion Inc (BMEA)

Biomea Fusion's stock price has declined significantly over the past six months. The company reported Q3 and Q2 2025 financial results, with shares gaining 6.4% and 0.6% respectively. Biomea Fusion highlighted the durable benefits of icovamenib in Type-2 Diabetes and presented long-term follow-up data at WCIRDC 2025. Positive 52-week follow-up results from the Phase II COVALENT-111 study of icovamenib in Type 2 Diabetes were reported, and the first patient was dosed in a Phase I study for BMF-650. Biomea Fusion outlined its 2026 execution priorities for its metabolic disease pipeline, including plans to initiate Phase IIb trials for icovamenib in Q1 2026, with data expected in Q4 2026, and anticipates 28-day weight-loss data from the Phase I study of BMF-650 in Q2 2026. D. Boral Capital maintained a "Buy" rating for BMEA with a $12.00 target price, and Rodman & Renshaw initiated coverage with a "Buy" rating and an $8 price target. Citigroup lowered its price target from $7.00 to $6.00 but maintained a "Buy" rating, while D. Boral Capital also lowered its target from $16.00 to $12.00, maintaining a "Buy" rating. Weiss Ratings reiterated a "sell (e+)" rating. Biomea Fusion insiders have bought more company stock than they sold in the past three months.

Information regarding demand seasonality for Biomea Fusion, Inc.'s products and services is not explicitly available, as the company is in the clinical stage of development and its products are not yet commercialized. Mentions of "BMEA Seasonality" refer to historical stock price movements rather than the demand for its unlaunched therapeutic products.

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral covalent small molecule drugs for genetically defined cancers and metabolic disorders, including diabetes and obesity. The company operates in the Healthcare sector, specifically in Biotechnology and Pharmaceuticals. Its lead product candidate, icovamenib (BMF-219), is undergoing Phase I/II clinical trials for type 1 and type 2 diabetes, acute myeloid leukemia, and other oncology indications. Biomea Fusion is also developing BMF-650, an oral next-generation GLP-1 receptor agonist, which is in a Phase I study for obesity.

Biomea Fusion, Inc. is headquartered in San Carlos, California, with mentions of Redwood City and Carlsbad, California. The company primarily conducts its research and early clinical operations within the United States and is exploring collaborations for later-stage development and global commercialization.

Biomea Fusion has generally maintained a "Moderate Buy" consensus rating from analysts, indicating a positive sentiment towards its prospects. The company's reputation has been bolstered by positive clinical data for icovamenib in diabetes. However, the substantial decline in its stock price over the last year could negatively impact investor perception and overall market reputation. The company's efforts to reduce expenses and streamline operations have been reported, which could be viewed favorably in terms of financial management.

Biomea Fusion, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional shareholders hold approximately 35.45% of the stock. Major institutional owners include Fmr Llc, Cormorant Asset Management, LP, and Vanguard Group Inc. Thomas Andrew Butler is the largest individual shareholder, holding 4.68 million shares, representing 6.61% of the company.